Trifluridine/tipiracil(TAS-102)-induced nausea and vomiting in patients with colorectal cancer: a prospective, observational, multicenter study
Latest Information Update: 07 Feb 2020
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
Most Recent Events
- 07 Feb 2020 New trial record